Tumor vaccination involving a humoral immune response against self-proteins

US10526387B2 · kind B2 · utility

Assignees

• BIONTECH PROTEIN THERAPEUTICS GMBH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Thorsten Klamp · Mainz, DE
• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Michael Koslowski · Mainz, DE
• Thomas Hiller · Mainz, DE
• Jens Schumacher · Heidelberg, DE

Key dates

• Filing date: Nov 2, 2016
• Grant date: Jan 7, 2020
• Expiry date: Nov 2, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2730/10171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.